上海现代制药股份有限公司 关于下属子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）下属子公司国药集团容 生制药有限公司（以下简称国药容生）、国药一心制药有限公司（以下简称国药 一心）分别收到国家药品监督管理局核准签发的《药品注册证书》。现将相关情 况公告如下： 一、盐酸咪达普利片 （一）药品基本信息 药品名称：盐酸咪达普利片 剂型：片剂 规格：5mg 证券代码：600420 证券简称：国药现代 公告编号：2025-058 注册分类：化学药品 4 类 证书编号：2025S02225 （二）药品研发及市场情况 药品批准文号：国药准字 H20254897 上市许可持有人：国药集团容生制药有限公司 药品生产企业：国药集团容生制药有限公司 申请事项：药品注册（境内生产） 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。 盐酸咪达普利片适用于治疗：1、原发性高血压；2、肾实质性病变所致继发 性 ...

4家企业均以"链式发展"构建产业竞争力。福瑞达生物深耕美妆产业27年，构建起涵盖护肤品、医疗器 械、工业旅游的全产业链，拥有专利170余项，主导或参与制定国家标准30余项，其研发的全球首个王 浆酸化妆品原料等成果，推动行业技术升级。 "福瑞达始于玻尿酸，但不止于玻尿酸，我们将以颐莲品牌文化大会打造独有文化IP。"该公司董事长高 春明在会上介绍，企业打造"生活美容+医学美容"双美生态，通过"5+N"品牌矩阵覆盖多细分领域，其 中颐莲品牌融合李清照文化推出联名产品，强化"中国高保湿"定位。 海信集团以技术立企，从家电领域延伸至半导体、智慧能源等高端产业，2024年带动25家产业链企业在 鲁投资或扩产，形成"芯片—面板—终端"全链条创新体系；华光国瓷自主研发的天然矿物骨质瓷热稳定 性达200℃，远超140℃的国际标准，无铅釉技术获国家专利，入选国宴用瓷；鲁花集团首创5S物理压榨 工艺破解花生油黄曲霉素难题，更构建"花生种植—加工—废弃物利用"的绿色循环链，实现全产业链增 值。 在品牌培育方面，4家企业也各有突破。福瑞达依托"妆药同源"基因打造五大核心品牌。高春明透露， 企业2024年完成国内首个王浆酸化妆品原料备案 ...

Policy Developments - The National Medical Products Administration (NMPA) has released a draft for public consultation regarding the adjustment of medical device classifications, aiming to optimize the registration and filing requirements for medical devices [1] Drug Approval - Yuyuan Pharmaceutical's YKYY029 injection has received clinical trial approval for treating hypertension, marking a significant step in the development of a novel siRNA drug [2] - Hengrui Medicine has received clinical trial approvals for four drugs, including SHR-8068 injection and Abediterib injection, with total R&D investments amounting to approximately 20.33 million yuan [3] Financial Reports - Microchip Biotech expects a net profit of 30.06 million yuan for the first half of 2025, driven by increased sales from new drug listings and optimized sales strategies [4] - China National Pharmaceutical Modern reported a 6.46% decline in net profit for the first half of the year, attributed to decreased sales and prices of certain antibiotics and other products [5] Capital Market - Tigermed announced the sale of its stake in Lixin Pharmaceutical for approximately 34.11 million USD, reflecting a strategic move in the context of the domestic pharmaceutical industry's consolidation [6] Industry Events - A breakthrough in brain-computer interface technology has been achieved in Shanghai, allowing patients with speech impairments to communicate through decoded brain activity [8] - Yuan Da Pharmaceutical's innovative nasal spray for dry eye treatment has received approval and its first prescriptions have been issued, providing a new treatment option for patients [9] Debt Resolution - Kangmei Pharmaceutical has reached a settlement agreement to resolve historical debt issues for 43.5 million yuan, facilitating the closure of related legal matters [10] Market Sentiment - Weier Pharmaceutical announced plans for its employee stock ownership platform to reduce its holdings by up to 1% of the company's shares, driven by shareholder funding needs [11]

0证券代码：6004200证券简称：国药现代0公告编号：2025-057 上海现代制药股份有限公司 2025年半年度业绩快报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 本公告所载上海现代制药股份有限公司（以下简称公司）2025年半年度主要财务数据为初步核算数据， 未经会计师事务所审计，具体数据以公司2025年半年度报告中披露的数据为准，提请投资者注意投资风 险。 2025年上半年，公司实现营业收入487,767.35万元，较去年同期下降18.16%；实现归属于上市公司股东 的净利润67,206.69万元，较去年同期下降6.46%；实现归属于上市公司股东的扣除非经常性损益的净利 润63,746.03万元，较去年同期下降6.72%。 报告期内，受市场供需影响，公司部分青霉素类原料药及中间体的销量、价格同比走低；制剂业务板 块，部分头孢类、激素类、神经类产品受药品集中采购及终端需求减少等因素影响，销售收入同比有所 下降。面对市场竞争压力，公司聚焦战略布局，积极推进科研开发，加大市场深耕力度，持续推进提质 增效、降本控费，期间费 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-057 上海现代制药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公告所载上海现代制药股份有限公司（以下简称公司）2025 年半年度主 要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司 2025 年 半年度报告中披露的数据为准，提请投资者注意投资风险。 一、2025年半年度主要财务数据和指标 | | | | | | | 单位：人民币元 | | | | --- | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | | 增减变动幅度（%） | | | 营业总收入 | 4,877,673,521.93 | 5,960,093,922.86 | | -18.16 | | | 营业利润 | 920,163,725.85 | 1,096,704,023.68 | | -16.10 | | | 利润总额 | 924,926,954.05 | 1,086,401,902.24 | | -14.86 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-057 上海现代制药股份有限公司 2025 年半年度业绩快报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本公告所载上海现代制药股份有限公司（以下简称公司）2025 年半年度主 要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司 2025 年 半年度报告中披露的数据为准，提请投资者注意投资风险。 一、2025年半年度主要财务数据和指标 单位：人民币元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（%） | | --- | --- | --- | --- | | 营业总收入 | 4,877,673,521.93 | 5,960,093,922.86 | -18.16 | | 营业利润 | 920,163,725.85 | 1,096,704,023.68 | -16.10 | | 利润总额 | 924,926,954.05 | 1,086,401,902.24 | -14.86 | | 归属于上市公司股东的净利润 | 672,066,877 ...

今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 动物疫苗 | 2.91 | 金属铅 | -1.27 | | 仿制药一致性评价 | 2.67 | 硅能源 | -1.22 | | 青蒿素 | 2.65 | 金属锌 | -1.18 | | 禽流感 | 2.33 | 稀土永磁 | -0.85 | | 阿尔茨海默概念 | 2.28 | 特钢概念 | -0.81 | | 海南自贸区 | 2.21 | PET铜箔 | -0.73 | | 肝炎概念 | 2.17 | PCB概念 | -0.72 | | 医药电商 | 2.00 | AI手机 | -0.70 | | 幽门螺杆菌概念 | 1.93 | 金属铜 | -0.67 | | 减速器 | 1.89 | 钛白粉概念 | -0.65 | 资金面上看，今日动物疫苗概念板块获主力资金净流入2.81亿元，其中，10股获主力资金净流入，6股 主力资金净流入超千万元，净流入资金居首的是生物股份，今日主力资金净流入1.59亿元，净流入资金 居前的还有海正药业、科兴制药、瑞普生物等，主力资金 ...

证券代码：600420 证券简称：国药现代 公告编号：2025-056 上海现代制药股份有限公司 2024年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.20元（含税） 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | A 股 | 2025/7/17 | － | 2025/7/18 | 2025/7/18 | 差异化分红送转：否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 6 月 26 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称中国结算上海分公司）登记在册的公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本1,341,172,692股为基数， ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen stock markets have announced significant updates, including changes in financing, business performance, and strategic decisions, which may impact investor sentiment and market dynamics [1]. Financing and Restructuring - Guanhao Biological has withdrawn its application for refinancing, leading to the termination of the review process by the Shenzhen Stock Exchange [3]. - Jinhongshun has terminated its major asset restructuring plan due to a lack of consensus among parties involved [6]. - Yuyuan Co. plans to issue bonds not exceeding 40 billion yuan to adjust its debt structure and replenish working capital [23]. Business Performance and Uncertainties - Aored has highlighted significant uncertainties in its computing power leasing services due to heavy asset investment and potential market fluctuations [4]. - Guoyao Modern intends to publicly transfer 51% of its subsidiary Guoyao Hason's shares, as the subsidiary has been underperforming with continuous losses since 2021 [5]. - Chengbang Co. reported that its subsidiary, Xinchun Electronics, has a small business scale and faces intense competition in the semiconductor storage industry, with projected revenues of 111 million yuan and a net profit of 933,800 yuan for 2024 [9]. Stock Market Activity - Alloy Investment announced a change in its controlling shareholder to Jiuzhou Hengchang, with stock trading resuming on July 1 [7]. - Changcheng Military Industry reported significant stock price volatility, with a cumulative increase of over 100% in the last 10 trading days, indicating potential irrational market behavior [8]. Earnings Forecasts - Hanyu Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, recovering from a loss in the previous year, driven by international business growth [12]. - Taotao Vehicle anticipates a net profit increase of 70.34% to 97.81% for the same period, reflecting strong sales performance [13]. - Weichai Heavy Machinery projects a net profit increase of 40% to 60%, benefiting from industry policy support and demand growth [15]. Major Contracts and Projects - China Railway has won contracts for overseas construction projects totaling approximately 5.343 billion yuan [17]. - Zhonggong International has signed a 175 million yuan engineering consulting service contract [18]. - Hezhan Energy has entered into a 177 million yuan contract for the sale of steel-concrete towers [19].